etelcalcetide

Also known as Velcalcetide

Etelcalcetide, sold under the brand name Parsabiv, is a calcimimetic medication for the treatment of secondary hyperparathyroidism in people undergoing hemodialysis. It is administered intravenously at the end of each dialysis session. Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.

Wikidata facts

Mass: 1047.529
Has use: medication

Show 7 more facts

medical condition treated: secondary hyperparathyroidism
canonical SMILES: CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C
chemical formula: C₃₈H₇₃N₂₁O₁₀S₂
isomeric SMILES: C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O
NCI Thesaurus ID: C129712
defined daily dose: 2.1
physically interacts with: calcium sensing receptor

Sources (3)

via Wikidata · CC0

~3 min read

Encyclopedic overview

10 sections

Contents

Medical uses
Pharmacodynamics
Mechanism of action
Pharmacokinetics
Side effects
Contraindications
Chemistry
History
Research
References

==Medical uses== Etelcalcetide is used for the treatment of secondary hyperparathyroidism in people with chronic kidney disease (CKD) on hemodialysis. Hyperparathyroidism is the condition of elevated parathyroid hormone (PTH) levels and is often observed in people with CKD.

Excerpted from Wikipedia’s “etelcalcetide” article, available under the CC BY-SA 4.0 licence.